Evidence map›Paper›PMID 40810358›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Background HIV Incidence in PURPOSE 1 and 2 PrEP Trials.

Jean-Jacques Parienti

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jean-Jacques ParientiDepartment of Biostatistics and Clinical Research, Caen University Hospital, Caen, France.ORCID 0000-0002-4774-5590

Funding

Caen-Normandie University
6 · The paper itself

Abstract

HIV incidence among low-adherence oral PrEP users in PURPOSE 1 and 2 closely matched or slightly exceeded background HIV incidence (bHIV), supporting bHIV as a conservative comparator in PrEP trials. This enables ethical, efficient evaluation of new prevention strategies without placebo arm.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAdultFemaleHumansIncidenceMaleMedication AdherenceAnti-HIV Agentsbackground HIV incidencecounterfactualdesignPrEP

Identifiers

PMID40810358
PMCPMC12728266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.